Is it worth completely resecting hepatoblastoma at diagnosis?
Mené sur 51 enfants atteints d'un hépatoblastome ayant été réséqué au moment du diagnostic, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité d'une chimiothérapie adjuvante à base de deux cycles de cisplatine, fluorouracile et vincristine (durée médiane de suivi : 42 mois)
Until recently, the value of complete resection at the time of hepatoblastoma diagnosis was unclear. However, two key study from the American Children's Oncology Group (COG) and the European Childhood Liver Tumors Strategy Group (SIOPEL) achieved similar outcomes in patients with localised hepatoblastoma who underwent resection using two different approaches: upfront resection in selected cases (COG AHEP0731) and delayed resection after preoperative chemotherapy in every case (all prevoius SIOPEL studies).
The Lancet Oncology , commentaire, 2018